Skip to main content

Table 5 Relation between GSTM1, GSTT1, CYP1A1 genotypes and clinical stages at diagnosis of PCa

From: Association of CYP1A1, GSTM1 and GSTT1 gene polymorphisms with risk of prostate cancer in Algerian population

Polymorphism Clinical stages OR/CI P value
Localized Advanced
(n = 42) (n = 59)
GSTM1
M+ 18 (42.85%) 25 (42.38%) 0.99 [0.85–1.16] 0.98
M 24 (57.15%) 34 (57.62%)
GSTT1
T+ 28 (66.66%) 35 (59.32%) 1.11 [0.94–1.31] 0.18
T 4 (33.34%) 24 (40.68%)
GSTM1/GSTT1
Both present 15 (35.71%) 15 (25.42%)   0.75
Either null 17 (40.48%) 29 (49.15%) 1.02 [0.87–1.20] 0.19
Both null 10 (23.81%) 15 (25.43%) 0.89 [0.75–1.06]  
CYP1A1
TT 33 (78.57%) 49 (83.05%) 0.84 [0.69–1.03] 0.10
TC 9 (21.43%) 10 (16.95%)